scholarly journals Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (30) ◽  
pp. 49749-49756 ◽  
Author(s):  
Shogo Hosogoe ◽  
Shingo Hatakeyama ◽  
Ayumu Kusaka ◽  
Itsuto Hamano ◽  
Yoshimi Tanaka ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Contrast Media ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Response ◽  
Advanced Renal Cell Carcinoma ◽  
Molecular Targeting ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy

scholarly journals Expression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapy

2010 ◽  
Vol 1 (4) ◽  
pp. 697-701 ◽  
Author(s):  
TAKASHI SEO ◽  
RYUICHIRO KONDA ◽  
JUN SUGIMURA ◽  
KAZUHIRO IWASAKI ◽  
YUSUKE NAKAMURA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Molecular Targeting ◽  
Promising Candidate ◽  
Targeting Therapy ◽  
Molecular Targeting Therapy ◽  
Inducible Protein

Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4636-4636
Author(s):  
Steffen Weikert ◽  
Viktor Grünwald ◽  
Ingo GH Schmidt-Wolf ◽  
Stefan Hauser ◽  
Kerstin Kapp ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Disease Control ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Cancer Vaccine ◽  
Renal Cell ◽  
Tumor Response ◽  
Advanced Renal Cell Carcinoma ◽  
Allogeneic Tumor

4636 Background: MGN1601 was tested in the first-in-man phase I-II clinical study in patients with advanced renal cell carcinoma (RCC) who failed several previous therapy lines and had no further standard therapy available. MGN1601 consists of two active pharmaceutical ingredients in fixed combination: fourfold gene-modified allogeneic tumor cells expressing IL-7, GM-CSF, CD80 and CD154 through MIDGE vectors and a TLR-9 agonist, the immunomodulator dSLIM. Methods: The ASET study is a multicentric, single-arm phase I-II clinical trial. Clinical response was evaluated using CT scans (RECIST 1.1 or immune related Response Criteria, irRC). Efficacy data were evaluated in terms of PFS and OS for the intended to treat and the treated per protocol (TPP) populations, clinical parameters and quality of life. Immune response was determined using DTH to MGN1601, LTT assay, frequency and activation of blood cells, and mRNA, chemokine and cytotoxic T cells analysis as well as tumor tissue evaluation. Results: Nine of 19 included patients completed the TPP, the others discontinued the study earlier due to PD. Median PFS in the TPP group was 12 wks (3 months) and OS (not reached yet) 46 wks (11 months). Three patients achieved disease control (1 PR, 2 SD) after 12 wks. Two patients are continuing treatment in the extension phase and are progression free since 37 and 46 wks, respectively. Re-evaluation of tumor response data using irRC revealed 1 additional patient with a delayed tumor response 4 wks after treatment stop. Herewith, 4 out of 9 TPP patients (45%) achieved disease control. Of 7 patients receiving targeted therapy upon stop of study treatment, 4 had substantial objective responses, providing evidence that the study drug is able to render their tumors more vulnerable to subsequent therapies. Immune analysis showed trends towards increases of T-, NKT-cell and pDC frequencies and other immune parameters in those patients with clinical responses, indicating anti-tumor immunity of study treatment. Conclusions: The therapeutic cancer vaccine MGN1601 shows promising efficacy in late stage mRCC patients. Results warrant further clinical studies with MGN1601.

Association of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patients.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 506-506 ◽  
Author(s):  
Norihiko Tsuchiya ◽  
Ryoma Igarashi ◽  
Naoko Suzuki-Honma ◽  
Nobuhiro Fujiyama ◽  
Shintaro Narita ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Response ◽  
Advanced Renal Cell Carcinoma ◽  
Therapeutic Drug ◽  
Whitney Test ◽  
Mann Whitney Test ◽  
Trough Levels

506 Background: Therapeutic drug monitoring (TDM) has been recognized as a useful tool for optimizing the dose of many drugs. The effectiveness of TDM for molecular targeted agents, however, has not so far been established. In this study, we examined the associations between pharmacokinetics of axitinib (AXI) and adverse events (AEs) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC). Methods: The pharmacokinetics of AXI was examined in 24 patients (18 males and 6 females) with aRCC. The plasma AXI levels were measured using high-performance liquid chromatography and a pharmacokinetic study was performed on day 7 in the first cycle. Subsequently, the associations between the pharmacokinetics of AXI and the occurrence and grade of AEs, best tumor response, and progression-free survival (PFS) were investigated. Results: All the patients were been treated with 10 mg/day of AXI at the day of pharmacokinetics and the trough levels were ranged between 1.2 and 70.97 ng/mL. The trough levels were significantly associated with the occurrence of hypertension, hyperthyroidism, and grade 1 or higher proteinuria (p=0.037, 0.024, 0.027 by Mann-Whitney test, respectively), and were associated with the best tumor response (by Mann-Whitney test, p=0.043) (Table 1). Patients with 5.0 ng/mL of higher trough levels of AXI showed a tendency toward longer PFS than those with the trough levels less than 5.0 ng/mL (Table 2). Conclusions: TDM of AXI in patients with aRCC may be useful to determine the adequate dose and prevent severe AEs. Further studies are mandatory to conclude the usefulness of TDM of AXI for the long-term clinical efficacy in patients with aRCC. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document